TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07354724: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Sponsor: Denali Therapeutics Inc. · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 32 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$4,307,460

Rescue Site Savings

+$2,836,620

Unlock Full NCT07354724 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07354724 Rescue Dossier →